Medical Device Update: China NMPA Registration Fee Changes — Key Takeaways

China’s National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú) has implemented revised registration and filing fees for medical devices effective 2025, with the largest increase hitting Class III initial registration fees at ¥216,000 RMB (approximately $29,800 USD)—a 30% rise from the previous ¥166,000 RMB. This marks the first significant fee adjustment since 2022, and it comes as foreign device makers are already navigating tightened clinical evaluation requirements and the new Market Authorization Holder (MAH) framework. Below, we break down what changed, why it matters, and how to plan your 2025–2026 China market entry budget.

What Changed: The New NMPA Fee Schedule

The NMPA fee overhaul, announced via the 2025 Notice on Adjusting Medical Device Registration Fees, applies to both domestic and foreign applicants. The biggest jumps hit the initial registration categories. Class II devices now cost ¥94,000 RMB (up from ¥72,000, a 30% increase), while Class III devices cost ¥216,000 RMB (up from ¥166,000, a 30% increase). Renewal and change fees rose modestly—Class III renewal went from ¥99,000 to ¥108,000 (9% increase). Critically, the fee for parallel application (submitting multiple similar models under one dossier) was introduced at ¥54,000 per additional model for Class III—a new cost that didn’t formally exist before.

Why the increase? NMPA states it reflects the rising costs of technical review, clinical evaluation oversight, and on-site manufacturing inspections (for foreign firms, these are conducted by NMPA-authorized overseas inspection teams). For foreign manufacturers, the impact is twofold: higher upfront capital commitment and a greater risk if registration is rejected (fees are non-refundable).

Fee Comparison: Class II vs. Class III vs. Filing

Note: All fees are non-refundable and paid upon submission. Renewal fees apply every 5 years for registered devices.

Why This Matters for Foreign Manufacturers

For overseas companies, the NMPA registration fee is just one component of a much larger market access cost. A typical Class III submission—including Chinese agent fees, dossier preparation, translation, clinical evaluation (if required), and on-site inspection support—now easily exceeds ¥2–3 million RMB ($280,000–$420,000). The fee increase adds ¥50,000–¥60,000 of direct cost, but the bigger impact is the signal: NMPA is raising the financial bar for registration, likely to encourage only serious, well-prepared applicants. Companies with multiple models face even higher costs due to the new parallel model fee.

Compare that to the US FDA’s 510(k) fee of $21,760 (standard, FY2025) or the EU MDR Notified Body review fees that can run €20,000–€50,000 per device. While NMPA’s ¥216,000 ($29,800) is not the highest globally, it is the only major market where fees are non-refundable and where rejection rates remain high—around 30–40% for first-time Class III submissions from foreign firms. The new fee schedule raises the stakes for dossier quality and regulatory strategy.

Timeline and Transition Rules

The new fees took effect April 1, 2025. Applications submitted before that date but not yet accepted by NMPA were subject to the old fee schedule if the submission was pre-filed before March 15. For any new application after April 1, the higher rates apply. The NMPA also introduced a fee waiver for small and medium enterprises (SMEs)—foreign companies with annual revenue below ¥50 million RMB can apply for a 50% reduction, though approval is discretionary and requires certified financial documents. This is a change that could benefit smaller innovative device makers, but the paperwork burden is non-trivial.

Key Pitfalls to Avoid

Strategic Recommendations for 2025–2026

1. Accelerate pending submissions. If you have a Class III device already in the final stages of dossier preparation, submitting before the next potential fee adjustment (anticipated 2027) locks in the current rate. Engage a Chinese regulatory agent now to pre-review your dossier—NMPA rejection rates for foreign firms remain high, and a single resubmission can double your fee exposure.

2. Bundle similar models. Use the new parallel model fee structure to your advantage. If you plan to register three similar Class III devices, the parallel model fee is ¥54,000 per additional model versus a full ¥216,000 for each separate application—a savings of ¥378,000 for three devices. This requires careful device classification grouping; work with an experienced Chinese regulatory consultant.

3. Evaluate the SME fee waiver. Foreign companies with global revenue under ¥50 million RMB (about $7 million USD) should strongly consider applying. The cost of preparing certified financial statements in Chinese is around ¥15,000–¥30,000—far less than the ¥108,000 savings. Consult your Chinese agent on eligibility documentation requirements.

NEXT STEPS

To make the most of these fee changes, consider these three actions:

• Review your current device portfolio against the new fee schedule. Use our NMPA Registration Checklist to ensure your dossier covers all fee-impacting parameters (model count, classification, clinical evidence).
• Consult with a Chinese regulatory agent to determine if your device qualifies for the SME fee waiver or a parallel application. Read our guide: How to Choose a Chinese Regulatory Agent.
• Plan your 2025–2026 budget with the new fees in mind. Download our China Medical Device Market Entry Cost Calculator to model total registration costs including fees, agents, and clinical evaluation.

— China Gateway 360 —
Remote China market entry support, built around execution.